Corporate Counsel WIth the Biopharmaceutical Firm UCB
About Anna Richo
With corporate law experience extending more than two decades, Anna Richo holds responsibilities as executive vice president and general counsel with the Brussels, Belgium, biopharmaceutical firm UCB. In this capacity, she serves on the firm’s executive committee and guides corporate compliance, intellectual property, and legal divisions. Anna Richo previously engaged with Thousand Oaks, California-based Amgen, Inc., as senior vice president and chief compliance officer. She spearheaded the creation and implementation of ethics and health care compliance programs encompassing more than 150 staff members worldwide.
WIth a DePaul University College of Law degree and Chicago private practice experience behind her, Ms. Richo joined Baxter International, Inc., in 1991. She managed global issues of risk exposure and mass tort litigation, and led the formation of litigation reserve funds totaling $1 billion. She also managed a team of nearly 20 employees in handling complex claims and product liability cases. Anna Richo is an accomplished public presenter who spoke before the Young Lawyers Section of the Chicago Bar Association on the topic “Going In-House: Career Transitioning From The Law Firm To The Corporate Legal Department.”
WBL to hold 15th Annual Summit in March 2016
With over 25 years of biotechnology and pharmaceutical experience, Anna Richo serves as executive vice president and general counsel of UCB in Brussels, Belgium. Anna Richo maintains membership in several organizations, including Women Business Leaders (WBL) of the U.S. Health Care Industry Foundation.
Registration is currently open for the 15th Annual WBL Summit, which will take place March 16-18, 2016, at the Ritz-Carlton on Amelia Island, Florida. An exclusive event, the summit is limited to 180 WBL members representing every area of the health care industry. The intimate nature of the three-day event provides attendees with the opportunity to build meaningful relationships while learning about the current challenges facing industry leaders.
Focused on the theme “Innovative Leadership,” the 2016 WBL Summit will feature educational sessions on a variety of topics, including brand building, emotional intelligence, and business negotiations. The event will also include presentations from a number of prominent speakers as well as casual networking activities such as breakfasts, dinners, and morning walks.
UCB Delivers 17 Presentations at 2015 International Epilepsy Congress
An experienced corporate attorney, Anna Richo has worked in the biotechnology and pharmaceutical industries for approximately 25 years. Following nine years at Amgen, Anna Richo became the executive vice president and general counsel of UCB, a Brussels, Belgium-based biopharmaceutical company that develops treatments for individuals with immunology disorders and central nervous system diseases such as epilepsy.
Recently, UCB was heavily involved in the 31st International Epilepsy Congress, which was held September 5-9, 2015, in Istanbul, Turkey. In total, the organization had 17 abstracts accepted for the event, including poster and oral presentations.
All of UCB’s presentations focused specifically on two anti-epileptic drugs it has developed: brivaracetam and VIMPAT, the brand name of the drug lacosamide. While brivaracetam is undergoing regulatory reviews for approval, VIMPAT has been approved in Europe to treat partial-onset seizures in adults.
During the congress, UCB presented the latest clinical findings surrounding both drugs and highlighted VIMPAT's effectiveness in preventing seizures and improving the lives of people with epilepsy. For a complete list of UCB’s presentations, visit www.ucb.com.